tiprankstipranks
Advertisement
Advertisement

HK:9966 Stock Latest News

Alphamab’s KN026 Phase III Breast Cancer Trial Hits Key Efficacy Goal
Company AnnouncementsAlphamab’s KN026 Phase III Breast Cancer Trial Hits Key Efficacy Goal
6d ago
9966
Alphamab Oncology Swings to Loss as R&D Spend Climbs but Cancer Pipeline Advances
PremiumCompany Announcements
Alphamab Oncology Swings to Loss as R&D Spend Climbs but Cancer Pipeline Advances
12d ago
9966
Alphamab Starts Phase III Trial of Next-Gen HER2 Drug in High-Risk Breast Cancer
PremiumCompany Announcements
Alphamab Starts Phase III Trial of Next-Gen HER2 Drug in High-Risk Breast Cancer
14d ago
9966
Alphamab Advances JSKN016 Into Phase III for Hard-to-Treat Breast Cancer
PremiumCompany Announcements
Alphamab Advances JSKN016 Into Phase III for Hard-to-Treat Breast Cancer
18d ago
9966
Alphamab Oncology Names New CFO as Capital Markets Vice President Resigns
PremiumCompany Announcements
Alphamab Oncology Names New CFO as Capital Markets Vice President Resigns
19d ago
9966
Alphamab Oncology Starts First-in-Human Trial of Novel Bispecific ADC JSKN027
PremiumCompany AnnouncementsAlphamab Oncology Starts First-in-Human Trial of Novel Bispecific ADC JSKN027
21d ago
9966
Alphamab Wins CDE Nod for First-in-Class Dual-Payload Cancer ADC JSKN021
Premium
Company Announcements
Alphamab Wins CDE Nod for First-in-Class Dual-Payload Cancer ADC JSKN021
25d ago
9966
Alphamab Oncology Sets Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
Alphamab Oncology Sets Board Meeting to Approve 2025 Annual Results
26d ago
9966
Alphamab Oncology Names Veteran Biologics Executive as Chief Technology Officer
PremiumCompany Announcements
Alphamab Oncology Names Veteran Biologics Executive as Chief Technology Officer
27d ago
9966
Alphamab Oncology’s KN035 NDA for First-Line Biliary Tract Cancer Accepted by China’s NMPA
PremiumCompany Announcements
Alphamab Oncology’s KN035 NDA for First-Line Biliary Tract Cancer Accepted by China’s NMPA
3M ago
9966
Alphamab Wins CDE Acceptance for Phase II Trial of Novel Cervical Cancer Therapy JSKN033
PremiumCompany Announcements
Alphamab Wins CDE Acceptance for Phase II Trial of Novel Cervical Cancer Therapy JSKN033
3M ago
9966
Alphamab Oncology’s JSKN003 Receives FDA Breakthrough Therapy Designation
PremiumCompany Announcements
Alphamab Oncology’s JSKN003 Receives FDA Breakthrough Therapy Designation
4M ago
9966
Alphamab Oncology Advances Revolutionary JSKN027 ADC to Clinical Stage
PremiumCompany AnnouncementsAlphamab Oncology Advances Revolutionary JSKN027 ADC to Clinical Stage
4M ago
9966
Alphamab Oncology Initiates HK$30 Million Share Repurchase Plan
Premium
Company Announcements
Alphamab Oncology Initiates HK$30 Million Share Repurchase Plan
5M ago
9966
Alphamab Oncology’s JSKN003 Gains U.S. FDA Fast Track Designation
Premium
Company Announcements
Alphamab Oncology’s JSKN003 Gains U.S. FDA Fast Track Designation
5M ago
9966
Alphamab Oncology’s JSKN003 Gains U.S. FDA Fast Track Designation
PremiumCompany Announcements
Alphamab Oncology’s JSKN003 Gains U.S. FDA Fast Track Designation
5M ago
9966
Alphamab Oncology Grants Award Shares to Key Personnel
PremiumCompany Announcements
Alphamab Oncology Grants Award Shares to Key Personnel
5M ago
9966
Alphamab Oncology’s JSKN003 Receives Breakthrough Therapy Designation for HER2+ CRC
PremiumCompany Announcements
Alphamab Oncology’s JSKN003 Receives Breakthrough Therapy Designation for HER2+ CRC
6M ago
9966
Alphamab Oncology’s JSKN003 Shows Promising Results in Cancer Treatment Trials
PremiumCompany Announcements
Alphamab Oncology’s JSKN003 Shows Promising Results in Cancer Treatment Trials
6M ago
9966
Alphamab Oncology Reports Promising Phase III Trial Results for KN026
PremiumCompany AnnouncementsAlphamab Oncology Reports Promising Phase III Trial Results for KN026
6M ago
9966
Alphamab Oncology Provides Additional Details on 2024 Annual Report
Premium
Company Announcements
Alphamab Oncology Provides Additional Details on 2024 Annual Report
6M ago
9966
Alphamab Oncology Announces HK$20 Million Share Repurchase Plan
Premium
Company Announcements
Alphamab Oncology Announces HK$20 Million Share Repurchase Plan
6M ago
9966

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >